Doxofylline as a steroid-sparing treatment in Mexican children with asthma

References

• The Global Asthma Report 2018. Auckland, New Zealand: Global Asthma Network; 2018. http://globalasthmareport.org/resources/Global_Asthma_Report_2018.pdf. [accessed 12 November 2021].
   Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention; 2018. www.ginasthma.org. [accessed 10 June 2021].
   Google Scholar
• Holgate ST, Wenzel S, Postma DS, Weiss ST, Renz H, Sly PD. Asthma. Nat Rev Dis Primers. 2015;1(1):15025. doi:10.1038/nrdp.2015.25.
   PubMed Web of Science ®Google Scholar
• Del-Rio-Navarro BE, Berber A, Reyes-Noriega N, Navarrete-Rodriguez EM, Garcia-Almaraz R, Merida-Palacio JV, Ellwood P, Garcia-Marcos AL. Have asthma symptoms in Mexico changed in the past 15 years? Time trends from the International Study of Asthma and Allergies in Childhood to the global asthma network. Allergol Immunopathol (Madr). 2021;49(1):1–10. doi:10.15586/aei.v49i1.35.
   Web of Science ®Google Scholar
• Del-Río-Navarro BE, Berber A, Reyes-Noriega N, Navarrete-Rodríguez EM, García-Almaraz R, Ellwood P, Garcia-Marcos L, Saucedo-Ramírez OJ, Mérida-Palacio VJ, Ramos-García BDC, et al. Global Asthma Network Phase I study in Mexico: prevalence of asthma symptoms, risk factors and altitude associations-a cross-sectional study. BMJ Open Resp Res. 2020;7(1):e000658. doi:10.1136/bmjresp-2020-000658.
   PubMed Web of Science ®Google Scholar
• Larenas-Linnemann D, Salas-Hernández J, Vázquez-García JC, Ortiz-Aldana I, Fernández-Vega M, Del Río-Navarro BE, Cano-Salas MDC, Luna-Pech JA, Ortega-Martell JA, Romero-Lombard J, et al. Mexican asthma guidelines: GUIMA 2017. Rev Alerg Mex. 2017;64Suppl(1):s11–s128. doi:10.29262/ram.v64i0.272.
   PubMedGoogle Scholar
• Allen DB. Inhaled corticosteroids and endocrine effects in childhood. Endocrinol Metab Clin North Am. 2020;49(4):651–665. doi:10.1016/j.ecl.2020.07.003.
   PubMed Web of Science ®Google Scholar
• Riffo-Vasquez Y, Venkatasamy R, Page CP. Steroid sparing effects of doxofylline. Pulm Pharmacol Ther. 2018;48:1–4. doi:10.1016/j.pupt.2017.10.008.
   PubMed Web of Science ®Google Scholar
• Crossingham I, Turner S, Ramakrishnan S, Fries A, Gowell M, Yasmin F, Richardson R, Webb P, O’Boyle E, Hinks TSC. Combination fixed-dose β agonist and steroid inhaler as required for adults or children with mild asthma: a Cochrane systematic review. BMJ Evid Based Med. 2021;27(3):178–184. doi:10.1136/bmjebm-2021-111764.
   PubMedGoogle Scholar
• Chauhan BF, Chartrand C, Ni Chroinin M, Milan SJ, Ducharme FM. Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev. 2015;2015(11):CD007949. doi:10.1002/14651858.CD007949.pub2.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Pauwels RA. Theophylline in the management of asthma: time for reappraisal? Eur Respir J. 1994;7(3):579–591. doi:10.1183/09031936.94.07030579.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. The effect of doxofylline in asthma and COPD. Respir Med. 2020;164:105904. doi:10.1016/j.rmed.2020.105904.
   PubMed Web of Science ®Google Scholar
• Oñatibia-Astibia A, Martínez-Pinilla E, Franco R. The potential of methylxanthine-based therapies in pediatric respiratory tract diseases. Respir Med. 2016;112:1–9. doi:10.1016/j.rmed.2016.01.022.
   PubMed Web of Science ®Google Scholar
• Bierman CW, William PV. Therapeutic monitoring of theophylline: rationale and current status. Clin Pharmacokinet. 1989;17(6):377–384. doi:10.2165/00003088-198917060-00002.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Hanania NA, Dini FL, Goldstein MF, Fairweather WR, Howard WW, Cazzola M. Impact of doxofylline compared to theophylline in asthma: a pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2). Pulm Pharmacol Ther. 2018;53:20–26. doi:10.1016/j.pupt.2018.09.007.
   PubMed Web of Science ®Google Scholar
• Page CP. Doxofylline: a "novofylline. Pulm Pharmacol Ther. 2010;23(4):231–234. doi:10.1016/j.pupt.2010.04.002.
   PubMed Web of Science ®Google Scholar
• Sankar J, Lodha R, Kabra SK. Doxofylline: the next generation methylxanthine. Indian J Pediatr. 2008;75(3):251–254. doi:10.1007/s12098-008-0054-1.
   PubMed Web of Science ®Google Scholar
• Talmon M, Massara E, Brunini C, Fresu LG. Comparison of anti-inflammatory mechanisms between doxofylline and theophylline in human monocytes. Pulm Pharmacol Ther. 2019;59:101851. doi:10.1016/j.pupt.2019.101851.
   PubMed Web of Science ®Google Scholar
• Goldstein MF, Chervinsky P. Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma – a double-blind randomized placebo-controlled multicentre clinical trial. Med Sci Monit. 2002;8(4):CR297–304.
   PubMedGoogle Scholar
• Margay SM, Farhat S, Kaur S, Teli HA. To study the efficacy and safety of doxofylline and theophylline in bronchial asthma. J Clin Diagnostic Res. 2015;9(4):FC05–8.
   PubMedGoogle Scholar
• Calzetta L, Matera MG, Goldstein MF, Fairweather WR, Howard WW, Cazzola M, Rogliani P. A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: the LESDA study. Pulm Pharmacol Ther. 2020;60:101883. doi:10.1016/j.pupt.2019.101883.
   PubMed Web of Science ®Google Scholar
• Bagnato GF. Tolerability of doxofylline in the maintenance therapy of pediatric patients with bronchial asthma. Eur Rev Med Pharmacol Sci. 1999;3(6):255–260.
   PubMedGoogle Scholar
• Rogliani P, Calzetta L, Ora J, Cazzola M, Matera MG. Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. Multidiscip Respir Med. 2019;14(1):25. doi:10.1186/s40248-019-0189-0.
   PubMed Web of Science ®Google Scholar
• van Mastbergen J, Jolas T, Allegra L, Page CP. The mechanism of action of doxofylline is unrelated to HDAC inhibition, PDE inhibition or adenosine receptor antagonism. Pulm Pharmacol Ther. 2012;25(1):55–61. doi:10.1016/j.pupt.2011.10.007.
   PubMed Web of Science ®Google Scholar
• Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, Plummer AL, Taylor DR, American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–615. doi:10.1164/rccm.9120-11ST.
   PubMed Web of Science ®Google Scholar
• S.p.A. AF. Ansimar - Doxofylline, Manufactured by ABC farmaceutici, Turin, Italy; 2019. https://www.abcfarmaceutici.it/uploads/news/40_file3_en.pdf. [accessed 2 December 2021].
   Google Scholar
• Italian Medicines Agency (AIFA). Doxofilina ABC; 2019. https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_002301_033876_FI.pdf&sys=m0b1l3. [accessed 2 December 2021].
   Google Scholar
• Incepta Pharmaceuticals Ltd. BrezofilTM - Doxofylline. Manufactured by Incepta Pharmaceuticals Ltd, Savar, Dhaka, Bangladesh; 2019. http://www.inceptapharma.com/downloads/1561361514_pdoc_Brezofil%20Leaflet.pdf. [accessed 2 December 2021].
   Google Scholar
• Patel YA, Patel P, Bavadia H, Dave J, Tripathi CB. A randomized, open labeled, comparative study to assess the efficacy and safety of controller medications as add on to inhaled corticosteroid and long-acting β2 agonist in the treatment of moderate-to-severe persistent asthma. J Postgrad Med. 2010;56(4):270–274. doi:10.4103/0022-3859.70937.
   PubMed Web of Science ®Google Scholar
• Rajanandh MG, Nageswari AD, Ilango K. Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second-line treatment? A randomized trial. Clin Ther. 2015;37(2):418–426. doi:10.1016/j.clinthera.2014.12.008.
   PubMed Web of Science ®Google Scholar
• Sandrini A, Taylor DR, Thomas PS, Yates DH. Fractional exhaled nitric oxide in asthma: an update. Respirology. 2010;15(1):57–70. doi:10.1111/j.1440-1843.2009.01616.x.
   PubMed Web of Science ®Google Scholar
• Petsky HL, Kew KM, Chang AB. Exhaled nitric oxide levels to guide treatment for children with asthma. Cochrane Database Syst Rev. 2016;11(11):CD011439. doi:10.1002/14651858.CD011439.pub2.
   PubMedGoogle Scholar
• Petsky HL, Cates CJ, Kew KM, Chang AB. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. Thorax. 2018;73(12):1110–1119. doi:10.1136/thoraxjnl-2018-211540.
   PubMed Web of Science ®Google Scholar
• Jones NR, Wang K, Yang Y, Heneghan C, Price CP, Van den Bruel A, Plüddemann A. Fractional exhaled nitric oxide monitoring in paediatric asthma management. Br J Gen Pract. 2017;67(664):531–532. doi:10.3399/bjgp17X693449.
   PubMed Web of Science ®Google Scholar
• Larenas-Linnemann D, Gochicoa-Rangel L, Macías-Weinmann A, Soto-Ramos M, Luna-Pech JA, Elizondo-Ríos A, Del Río-Navarro BE, Hernández-Colín DD, García-Maldonado S, Zepeda B, et al. Consenso mexicano en relación con la fracción exhalada de óxido nítrico (FeNO) en asma 2020 [Mexican consensus on fractional exhaled nitric oxide (FeNO) in asthma 2020]. Rev Alerg Mex. 2020;67Suppl 2:S1–S25. doi:10.29262/ram.v67i0.760.
   PubMedGoogle Scholar
• Da Silva Salviano LD, Taglia-Ferre KD, Lisboa S, Costa ACCD, Campos HDS, March MFP. Association between fraction of exhaled nitric oxide and spriometry data and clinical control of asthma in children and adolescents. Rev Paul Pediatr. 2018;36(1):17–24. doi:10.1590/1984-0462/;2018;36;1;00015.
   Google Scholar
• Fielding S, Pijnenburg M, de Jongste JC, Pike KC, Roberts G, Petsky H, Chang AB, Fritsch M, Frischer T, Szefler S, et al. Change in FEV1 and feno measurements as predictors of future asthma outcomes in children. Chest. 2019;155(2):331–341. doi:10.1016/j.chest.2018.10.009.
   PubMed Web of Science ®Google Scholar
• Lipworth B, Kuo CR, Chan R. 2020 updated asthma guidelines: clinical utility of fractional exhaled nitric oxide (Feno) in asthma management. J Allergy Clin Immunol. 2020;146(6):1281–1282. doi:10.1016/j.jaci.2020.03.006.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Reddel HK, Eriksson G, Peterson S, Ostlund O, Sears MR, Jenkins C, Humbert M, Buhl R, Harrison TW, et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol. 2010;125(3):608.e1–608.e6. doi:10.1016/j.jaci.2009.11.033.
   Web of Science ®Google Scholar
• Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O’Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med. 1997;337(20):1412–1418. doi:10.1056/NEJM199711133372002.
   PubMed Web of Science ®Google Scholar
• Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N, Steffen H, Leichtl S, Rathgeb F, Keller A, Steinijans VW. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J. 1997;10(12):2754–2760. doi:10.1183/09031936.97.10122754.
   PubMed Web of Science ®Google Scholar
• Lim S, Jatakanon A, Gordon D, Macdonald C, Chung KF, Barnes PJ. Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice. Thorax. 2000;55(10):837–841. doi:10.1136/thorax.55.10.837.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Theophylline. Am J Respir Crit Care Med. 2013;188(8):901–906. doi:10.1164/rccm.201302-0388PP.
   PubMed Web of Science ®Google Scholar
• Mennini FS, Sciattella P, Marcellusi A, Marcobelli A, Russo A, Caputi AP. Treatment plan comparison in acute and chronic respiratory tract diseases: an observational study of doxophylline vs. theophylline. Expert Rev Pharmacoecon Outcomes Res. 2017;17(5):503–510. doi:10.1080/14737167.2017.1301815.
   PubMed Web of Science ®Google Scholar